JP2023515862A5 - - Google Patents

Info

Publication number
JP2023515862A5
JP2023515862A5 JP2022552382A JP2022552382A JP2023515862A5 JP 2023515862 A5 JP2023515862 A5 JP 2023515862A5 JP 2022552382 A JP2022552382 A JP 2022552382A JP 2022552382 A JP2022552382 A JP 2022552382A JP 2023515862 A5 JP2023515862 A5 JP 2023515862A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
wing
oligonucleotide according
independently
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552382A
Other languages
English (en)
Japanese (ja)
Other versions
JP7873170B2 (ja
JP2023515862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019874 external-priority patent/WO2021178237A2/en
Publication of JP2023515862A publication Critical patent/JP2023515862A/ja
Publication of JP2023515862A5 publication Critical patent/JP2023515862A5/ja
Priority to JP2026019212A priority Critical patent/JP2026109618A/ja
Application granted granted Critical
Publication of JP7873170B2 publication Critical patent/JP7873170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552382A 2020-03-01 2021-02-26 オリゴヌクレオチド組成物及びその方法 Active JP7873170B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026019212A JP2026109618A (ja) 2020-03-01 2026-02-09 オリゴヌクレオチド組成物及びその方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062983742P 2020-03-01 2020-03-01
US62/983,742 2020-03-01
US202063111071P 2020-11-08 2020-11-08
US63/111,071 2020-11-08
PCT/US2021/019874 WO2021178237A2 (en) 2020-03-01 2021-02-26 Oligonucleotide compositions and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026019212A Division JP2026109618A (ja) 2020-03-01 2026-02-09 オリゴヌクレオチド組成物及びその方法

Publications (3)

Publication Number Publication Date
JP2023515862A JP2023515862A (ja) 2023-04-14
JP2023515862A5 true JP2023515862A5 (cg-RX-API-DMAC7.html) 2024-03-05
JP7873170B2 JP7873170B2 (ja) 2026-06-11

Family

ID=77614463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552382A Active JP7873170B2 (ja) 2020-03-01 2021-02-26 オリゴヌクレオチド組成物及びその方法
JP2026019212A Pending JP2026109618A (ja) 2020-03-01 2026-02-09 オリゴヌクレオチド組成物及びその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026019212A Pending JP2026109618A (ja) 2020-03-01 2026-02-09 オリゴヌクレオチド組成物及びその方法

Country Status (8)

Country Link
US (1) US20230295619A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114939A4 (cg-RX-API-DMAC7.html)
JP (2) JP7873170B2 (cg-RX-API-DMAC7.html)
CN (1) CN115210377A (cg-RX-API-DMAC7.html)
AU (1) AU2021230473A1 (cg-RX-API-DMAC7.html)
CA (1) CA3169252A1 (cg-RX-API-DMAC7.html)
TW (1) TW202146650A (cg-RX-API-DMAC7.html)
WO (1) WO2021178237A2 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA43822A (fr) 2016-03-13 2018-11-28 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
TWI866002B (zh) * 2021-12-29 2024-12-11 財團法人生物技術開發中心 反義寡核苷酸及其用途
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
KR20260046111A (ko) * 2023-08-01 2026-04-06 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 MAPT를 표적으로 하는 dsRNA 및 이의 의약적 용도
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI702046B (zh) * 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
JP2019516679A (ja) * 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 生物活性剤に関する方法および組成物
CA3098624A1 (en) * 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
TWI862501B (zh) * 2018-07-03 2024-11-21 瑞士商赫孚孟拉羅股份公司 用於調制 Tau 表現之寡核苷酸

Similar Documents

Publication Publication Date Title
JP2022532169A5 (cg-RX-API-DMAC7.html)
JP2022550915A5 (cg-RX-API-DMAC7.html)
JP2020534253A5 (cg-RX-API-DMAC7.html)
JP2022551124A5 (cg-RX-API-DMAC7.html)
JP2025165976A5 (cg-RX-API-DMAC7.html)
JP2021526823A5 (cg-RX-API-DMAC7.html)
JP2005518402A5 (cg-RX-API-DMAC7.html)
JP7478210B2 (ja) 修飾オリゴヌクレオチド及び使用方法
JP2021512629A5 (cg-RX-API-DMAC7.html)
JP2023109824A (ja) GalNAc誘導体
HRP20211051T1 (hr) Pripravci namijenjeni moduliranju eksprimiranja tau
JP7690979B2 (ja) 一本鎖オリゴヌクレオチド
JP2019525918A5 (cg-RX-API-DMAC7.html)
JP2020522265A5 (cg-RX-API-DMAC7.html)
US20160331835A1 (en) Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2023022229A5 (cg-RX-API-DMAC7.html)
RU2015119409A (ru) Конъюгаты олигонуклеотидов
JP2021515784A5 (cg-RX-API-DMAC7.html)
KR20220148241A (ko) Pd-l1을 표적화하기 위한 방법 및 조성물
JP2019518759A (ja) オリゴヌクレオチドの精製のための疎水性相互作用クロマトグラフィー
WO2015108047A1 (ja) 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
CN111868068A (zh) 用于在tau蛋白病变治疗中使用的经修饰的寡核苷酸
AU2017205650A1 (en) Therapeutic compositions and methods for treating hepatitis b
JP7797016B2 (ja) Il-21に対するアプタマーおよびその使用
Seio et al. Synthesis and properties of cationic 2′-O-[N-(4-aminobutyl) carbamoyl] modified oligonucleotides